Biodesix, Inc. (BDSX)
NASDAQ: BDSX · Real-Time Price · USD
21.26
+0.08 (0.38%)
Oct 26, 2026, 4:00 PM EDT - Market closed
Biodesix Revenue
Biodesix had revenue of $26.86M in the quarter ending June 30, 2026, with 34.18% growth. This brings the company's total for the last twelve months to $102.94M, up 34.46% year-over-year. In the year 2025, Biodesix had annual revenue of $88.50M with 24.08% growth. That makes Biodesix the 22,423rd largest company in the world by revenue and 3,272nd in the United States.
Revenue (ttm)
$102.94M
Revenue Growth
+34.46%
P/S Ratio
2.18
Revenue / Employee
$308,201
Employees
334
Market Cap
224.32M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 88.50M | 17.18M | 24.08% |
| Dec 31, 2024 | 71.32M | 22.24M | 45.30% |
| Dec 31, 2023 | 49.09M | 10.88M | 28.46% |
| Dec 31, 2022 | 38.21M | -16.29M | -29.89% |
| Dec 31, 2021 | 54.51M | 8.95M | 19.64% |
| Dec 31, 2020 | 45.56M | 21.01M | 85.55% |
| Dec 31, 2019 | 24.55M | 4.12M | 20.16% |
| Dec 31, 2018 | 20.43M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Myriad Genetics | 806.60M |
| OPKO Health | 587.90M |
| GeneDx Holdings | 454.43M |
| Castle Biosciences | 357.28M |
| Fulgent Genetics | 323.93M |
| Burning Rock Biotech | 73.70M |
| Exagen | 71.12M |
| Freenome | 35.41M |
BDSX News
- 5 days ago - Biodesix to Report Third Quarter 2026 Financial Results on November 5, 2026 - GlobeNewsWire
- 7 days ago - American College of Chest Physicians Publishes New Framework for Lung Nodule Programs Recommending Biomarkers for Risk Stratification - GlobeNewsWire
- 8 days ago - Biodesix Adds Digital Diagnostics to Lung Pipeline, Creating New Growth Platform Combining Blood and Imaging Biomarkers - GlobeNewsWire
- 14 days ago - Biodesix price target raised to $40 from $30 at TD Cowen - TheFly
- 14 days ago - Biodesix to Present New Real-World Evidence Supporting Integration of Nodify Lung® Testing into Routine Lung Nodule Care at CHEST 2026 - GlobeNewsWire
- 4 weeks ago - Biodesix price target raised to $38 from $27 at H.C. Wainwright - TheFly
- 4 weeks ago - Biodesix advances two programs for Molecular Residual Disease monitoring - TheFly
- 4 weeks ago - Biodesix Advances Two Complementary Approaches to Molecular Residual Disease (MRD) Monitoring - GlobeNewsWire